Given the increasing use of targeted radionuclide therapies, such as PRLT in prostate cancer, where 177Lu-PSMA and 225Ac-PSMA represent the most commonly employed radiopharmaceuticals, it is imperative to evaluate whether the usage of PARPi can improve the efficacy of this therapeutic modality. This evidence concerns the gene FOLH1 and prostate cancer.